Skip to main content

Table 3 Summary of participant characteristics

From: A systematic review of mitochondrial abnormalities in myalgic encephalomyelitis/chronic fatigue syndrome/systemic exertion intolerance disease

Reference Dx Sample (n) Age (years, average (SD) Sex, female (%) Illness duration Marker assessed Sample source
ME/CFS/SEID HC ME/CFS/SEID HC ME/CFS/SEID HC
Armstrong et al. [5] Canadian Criteria 34 25 34.9 (1.8 SE) 33.0 (1.6 SE) 100% 100% NR Metabolites Whole blood and urine
Billing-Ross et al. [6] Fukuda Criteria,
Canadian Criteria
193 196 NR NR NR NR NR mtDNA DNA
Booth et al. [7] Fukuda Criteria 138 53 Cohort 1: 45.1 (11.8)
Cohort 2: 41.1 (12.1)
35.9 (13.4) Cohort 1: 79%
Cohort 2: 70%
76% NR ATP Neutrophils
Castro-Marrero et al. [8] Fukuda Criteria 23 15 44.1 (3.8) 43.5 (5.4) 65.2% 66.7% 15.6 (10.8) CoQ10, ATP, lipid peroxidation, Mitochondrial citrate
synthase activity, mTDNA, Expression levels of peroxisome proliferator-activated
receptor gamma-coactivator 1-alpha and transcription factor A
PBMCs
Germain et al. [9] Fukuda Criteria,
IOM 2015
17 15 53.9 (6.2) 51.9 (6.2) 100% 100% NR Metabolites Whole blood
Light et al. [10] Fukuda criteria 39 22 40–79 40–79 NR NR NR mRNA Leukocytes
Maes et al. [11] Fukuda Criteria 58 22 38.5 (13.9) 45.4 (10.1) 86.2% 77.3% NR Coenzyme Q10 Plasma
Mandarano et al. [12] Canadian Criteria 53 45 50.8 (16.2) 50.2 (17.5) 58.5% 57.8% 21.7 Mitochondria T cells
Missailidis et al. [22] Canadian Criteria 51 22 26–70 21–58 86% 68% NR Mitochondria Lymphoblasts
Missailidis et al. [23] Canadian Criteria 51 22 26–70 21–58 86% 68% NR Mitochondria PBMCs
Lymphoblasts
Naviaux et al. [13] Canadian Criteria,
Fukuda Criteria,
IOM 2015
45 39 F: 52 (2.5)
M: 53 (2.8)
F: 48 (2.8)
M: 53 (3.5)
51.1% 53.8% F: 17 (2.3)
M: 21 (3.0)
Metabolites Plasma
Nguyen et al. [14] Fukuda Criteria 17 19 48.68 (1.06) 46.48 (1.22) 82.4% 68.4% 8.4 TRPM3 surface expression NK cells, B lymphocytes
Nguyen et al. [15] Fukuda Criteria,
International Consensus
Criteria
6 6 50.33 (4.95) 50.00 (5.04) 83.3% 83.3% NR Mitochondria NK cells
Plioplys and Plioplys [16] Fukuda Criteria 15 15 18–58 19–58 53.3% 53.3% 8 months–20 years Mitochondria Percutaneous needle muscle biopsies
Shungu et al. [17] Fukuda Criteria 15 13 32.7 (8.6) 27.6 (7.4) 80% 53.8% 9.7 (9.1) Metabolites Cerebrospinal fluid
Sweetman et al. [18] Canadian Criteria 10 10 36.4 38.8 60% 60% 12.6 RNA PBMCs
Tomas et al. [19] Fukuda Criteria 52 35 42.8 (13.7) 36.6 (12.0) 84.6% 77.1% NR Mitochondria PBMCs
Venter et al. [20] Fukuda Criteria UK: 89 moderate, 29 severe
RSA: 143 moderate
UK: 64
RSA:98
NR NR NR NR NR mtDNA mtDNA
Yamano et al. [21] Fukuda Criteria Training: 47
Validation: 20
Training: 46
Validation: 20
Training: 38.08 (6.57)
Validation: 36.15 (8.14)
Training: 38.78 (9.71)
Validation: 36.10 (8.35)
Training: 87.2%
Validation: 100%
Training: 89.1%
Validation: 100%
NR Metabolites Plasma
  1. ATP adenosine triphosphate, CoQ10 Coenzyme Q10, DNA deoxyribonucleic acid, Dx diagnostic criteria, F female, HC healthy control, IOM Institute of Medicine, M male, mtDNA mitochondrial deoxyribonucleic acid, ME/CFS/SEID myalgic encephalomyelitis/chronic fatigue syndrome/systemic exertion intolerance disease, NK natural killer, NR not recorded, N number, PBMCs peripheral blood mononuclear cells, RSA Republic of South Africa, RNA ribonucleic acid, SD standard deviation, TRPM3 transient receptor potential melastatin 3, UK United Kingdom
\